These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Impact of combined lipid lowering and blood pressure control on coronary plaque: myocardial ischemia treated by percutaneous coronary intervention and plaque regression by lipid lowering and blood pressure controlling assessed by intravascular ultrasonography (MILLION) study. Kawashiri MA; Sakata K; Hayashi K; Gamou T; Kanaya H; Miwa K; Ueda K; Higashikata T; Mizuno S; Michishita I; Namura M; Nitta Y; Katsuda S; Okeie K; Hirase H; Tada H; Uchiyama K; Konno T; Ino H; Nagase K; Yamagishi M; Heart Vessels; 2017 May; 32(5):539-548. PubMed ID: 27798731 [TBL] [Abstract][Full Text] [Related]
9. PCSK9: is it fluoride for cardiology? King SB JACC Cardiovasc Interv; 2014 Nov; 7(11):1331-2. PubMed ID: 25459045 [No Abstract] [Full Text] [Related]
10. A new activity of N-cholinolytic drug benzohexonium. Khnychenko LK; Okunevich IV; Losev NA; Sapronov NS; Yakovleva EE Bull Exp Biol Med; 2012 Aug; 153(4):487-9. PubMed ID: 22977852 [TBL] [Abstract][Full Text] [Related]
11. Impact of plaque imaging by electron beam tomography on the treatment of dyslipidemias. Hecht HS Am J Cardiol; 2001 Aug; 88(4):406-8. PubMed ID: 11545763 [No Abstract] [Full Text] [Related]
12. Current status of lipid management in acute coronary syndrome. Fujisue K; Tsujita K J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524 [TBL] [Abstract][Full Text] [Related]
13. Evaluating Statin Versus Statin Plus Ezetimibe for Coronary Plaque Regression. Mascitelli L; Goldstein MR J Am Coll Cardiol; 2015 Dec; 66(25):2916. PubMed ID: 26718684 [No Abstract] [Full Text] [Related]
14. Impacts of estimated glomerular filtration rate on coronary atherosclerosis and plaque composition before and during statin therapy in patients with normal to mild renal dysfunction: subanalysis of the TRUTH study. Nozue T; Yamamoto S; Tohyama S; Fukui K; Umezawa S; Onishi Y; Kunishima T; Hibi K; Terashima M; Michishita I; Nephrology (Carlton); 2012 Sep; 17(7):628-35. PubMed ID: 22708952 [TBL] [Abstract][Full Text] [Related]
16. Plaque vulnerability at non-culprit lesions in obese patients with coronary artery disease: Frequency-domain optical coherence tomography analysis. Kataoka Y; Hammadah M; Puri R; Duggal B; Uno K; Kapadia SR; Tuzcu EM; Nissen SE; Nicholls SJ Eur J Prev Cardiol; 2015 Oct; 22(10):1331-9. PubMed ID: 26232281 [TBL] [Abstract][Full Text] [Related]
17. Triglycerides: how much credit do they deserve? Kohli P; Cannon CP Med Clin North Am; 2012 Jan; 96(1):39-55. PubMed ID: 22391250 [TBL] [Abstract][Full Text] [Related]
18. Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression After PCI: PRECISE-IVUS. Giral P; Hansel B; Chapman J J Am Coll Cardiol; 2016 Jan; 67(2):234. PubMed ID: 26791072 [No Abstract] [Full Text] [Related]
19. Reply: Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression After PCI: PRECISE-IVUS. Tsujita K; Sugiyama S; Shimomura H; Yamanaga K; Kaikita K; Hokimoto S; Ogawa H; J Am Coll Cardiol; 2016 Jan; 67(2):234-235. PubMed ID: 26791071 [No Abstract] [Full Text] [Related]
20. Getting What the Guidelines Stated Matters. Stone NJ; Lloyd-Jones D; Smith S J Am Coll Cardiol; 2016 Jan; 67(1):119-20. PubMed ID: 26764076 [No Abstract] [Full Text] [Related] [Next] [New Search]